Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235688 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors
A Phase 1 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02235688 is a Phase 1 study that has completed, run by ImmunityBio. The registered enrollment target is 30 participants.
The verdict
NCT02235688, a Phase 1 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 1 study to investigate the safety and activity of aldoxorubicin plus gemcitabine in Subjects with solid tumors.
Interventions
- DRUG gemcitabine
- DRUG aldoxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-08 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02235688
The ClinicalTrials.gov registry entry for NCT02235688 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which gemcitabine is the first listed.
NCT02235688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02235688 about?
NCT02235688 is a clinical study titled "Study to Investigate the Safety and Activity of Aldoxorubicin Plus Gemcitabine in Subjects With Metastatic Solid Tumors". This is a Phase 1 study to investigate the safety and activity of aldoxorubicin plus gemcitabine in Subjects with solid tumors.
What is the current status of trial NCT02235688?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-08. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02235688?
The interventions under investigation include: gemcitabine (DRUG), aldoxorubicin (DRUG).
Who is sponsoring clinical trial NCT02235688?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.